Enhanced pH-Sensitive Liposome Compositions for Targeted Cargo Delivery

Improved liposome compositions and methods for targeted cargo delivery, featuring modified pHLIP polypeptides that enhance membrane fusion efficiency, stability, and specificity, resulting in increased cargo delivery efficiency and reduced off-target effects.

The original patent disclosed liposome compositions and methods for delivering molecules to cells, but faced limitations in terms of membrane fusion efficiency, liposome stability, and targeting specificity. The new inventive concept addresses these limitations by introducing modified pHLIP polypeptides that improve the overall performance of the liposome-based cargo delivery system.

The enhanced pH-sensitive liposome compositions comprise modified pHLIP polypeptides with increased membrane fusion efficiency, achieved through modifications that enhance binding affinity to target cell membranes. Additionally, the liposomes are stabilized by attaching the pHLIP polypeptide to a polymer with a molecular weight of at least 10,000 Da, reducing aggregation and increasing cargo delivery efficiency. Furthermore, the modified pHLIP polypeptides selectively target cancer cells with low extracellular pH, reducing off-target effects. The system also enables real-time monitoring of cargo delivery through the release of a fluorescent marker upon membrane fusion.

The new claims introduce novel modifications to the pHLIP polypeptide, including increased membrane fusion efficiency, improved stability, and enhanced targeting specificity, which are not obvious from the original patent. These modifications provide a significant improvement over the existing technology, enabling more efficient and targeted cargo delivery.

Alternative embodiments of the inventive concept could include using different types of polymers or molecular weights to stabilize the liposomes, or modifying the pHLIP polypeptide to target different cell types or diseases. Additionally, the system could be adapted for use with different types of cargo, such as nucleic acids or small molecules.

The enhanced pH-sensitive liposome compositions and methods have significant commercial potential in the fields of cancer therapy, gene therapy, and vaccine development, where targeted and efficient cargo delivery is crucial. The market for liposome-based delivery systems is expected to grow significantly in the coming years, driven by the increasing need for effective and targeted therapies.